• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者来源的类器官在精准肿瘤医学中的应用。

Patient-derived organoids in precision cancer medicine.

机构信息

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

出版信息

Med. 2024 Nov 8;5(11):1351-1377. doi: 10.1016/j.medj.2024.08.010. Epub 2024 Sep 27.

DOI:10.1016/j.medj.2024.08.010
PMID:39341206
Abstract

Organoids are three-dimensional (3D) cultures, normally derived from stem cells, that replicate the complex structure and function of human tissues. They offer a physiologically relevant model to address important questions in cancer research. The generation of patient-derived organoids (PDOs) from various human cancers allows for deeper insights into tumor heterogeneity and spatial organization. Additionally, interrogating non-tumor stromal cells increases the relevance in studying the tumor microenvironment, thereby enhancing the relevance of PDOs in personalized medicine. PDOs mark a significant advancement in cancer research and patient care, signifying a shift toward more innovative and patient-centric approaches. This review covers aspects of PDO cultures to address the modeling of the tumor microenvironment, including extracellular matrices, air-liquid interface and microfluidic cultures, and organ-on-chip. Specifically, the role of PDOs as preclinical models in gene editing, molecular profiling, drug testing, and biomarker discovery and their potential for guiding personalized treatment in clinical practice are discussed.

摘要

类器官是三维(3D)培养物,通常源自干细胞,可复制人体组织的复杂结构和功能。它们为解决癌症研究中的重要问题提供了一个具有生理相关性的模型。从各种人类癌症中生成患者来源的类器官(PDO)可深入了解肿瘤异质性和空间组织。此外,研究非肿瘤基质细胞增加了研究肿瘤微环境的相关性,从而提高了 PDO 在个性化医学中的相关性。PDO 是癌症研究和患者护理的重大进展,标志着向更具创新性和以患者为中心的方法的转变。这篇综述涵盖了 PDO 培养的各个方面,以解决肿瘤微环境的建模问题,包括细胞外基质、气液界面和微流控培养以及器官芯片。具体讨论了 PDO 作为基因编辑、分子谱分析、药物测试、生物标志物发现的临床前模型的作用及其在指导临床实践中个性化治疗的潜力。

相似文献

1
Patient-derived organoids in precision cancer medicine.患者来源的类器官在精准肿瘤医学中的应用。
Med. 2024 Nov 8;5(11):1351-1377. doi: 10.1016/j.medj.2024.08.010. Epub 2024 Sep 27.
2
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.前列腺癌中的患者来源类器官:提高精准医学中的治疗效果。
Mol Cancer. 2021 Sep 29;20(1):125. doi: 10.1186/s12943-021-01426-3.
3
Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.从内镜活检和手术组织中开发患者来源的胃癌类器官。
Ann Surg Oncol. 2018 Sep;25(9):2767-2775. doi: 10.1245/s10434-018-6662-8. Epub 2018 Jul 12.
4
Tumor organoid models in precision medicine and investigating cancer-stromal interactions.肿瘤类器官模型在精准医学中的应用及肿瘤微环境相互作用的研究
Pharmacol Ther. 2021 Feb;218:107668. doi: 10.1016/j.pharmthera.2020.107668. Epub 2020 Aug 24.
5
Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.患者来源类器官作为癌症患者的治疗筛选平台。
Adv Healthc Mater. 2024 Aug;13(21):e2302331. doi: 10.1002/adhm.202302331. Epub 2024 Mar 1.
6
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.患者来源的肺类器官的体外药物测试,用于预测个体化药物治疗反应。
Lung Cancer. 2024 Apr;190:107533. doi: 10.1016/j.lungcan.2024.107533. Epub 2024 Mar 14.
7
Converging bioprinting and organoids to better recapitulate the tumor microenvironment.融合生物打印和类器官以更好地模拟肿瘤微环境。
Trends Biotechnol. 2024 May;42(5):648-663. doi: 10.1016/j.tibtech.2023.11.006. Epub 2023 Dec 9.
8
Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.患者来源的类器官在人类癌症中的应用:基础研究和精准医学的平台。
Mol Biomed. 2024 Feb 12;5(1):6. doi: 10.1186/s43556-023-00165-9.
9
Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.患者来源的功能性类器官作为一种针对肝胆癌的个体化药物筛选方法。
Adv Cancer Res. 2022;156:319-341. doi: 10.1016/bs.acr.2022.01.011. Epub 2022 Mar 16.
10
Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-derived Organoids.利用患者来源的类器官研究结直肠癌干细胞的新前景。
Curr Cancer Drug Targets. 2022;22(3):195-208. doi: 10.2174/1568009622666220117124546.

引用本文的文献

1
Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives.用于转化研究和精准医学的患者来源类器官生物样本库:挑战与未来展望
J Pers Med. 2025 Aug 21;15(8):394. doi: 10.3390/jpm15080394.
2
Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist's perspective.患者来源的类器官作为研究输卵管卵巢癌的模型:病理学家的观点
J Ovarian Res. 2025 Aug 20;18(1):191. doi: 10.1186/s13048-025-01766-4.
3
Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.
个性化治疗中的癌症干细胞:机制、微环境相互作用及治疗弱点
Front Cell Dev Biol. 2025 Jul 30;13:1619597. doi: 10.3389/fcell.2025.1619597. eCollection 2025.
4
Immunomodulatory Natural Products in Cancer Organoid-Immune Co-Cultures: Bridging the Research Gap for Precision Immunotherapy.癌症类器官-免疫共培养中的免疫调节天然产物:弥合精准免疫治疗的研究差距
Int J Mol Sci. 2025 Jul 26;26(15):7247. doi: 10.3390/ijms26157247.
5
CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook.CRISPR/Cas技术在胰腺癌研究与治疗中的应用:最新进展与未来展望
Discov Oncol. 2025 Aug 11;16(1):1530. doi: 10.1007/s12672-025-03383-5.
6
Tumor organoids in immunotherapy: from disease modeling to translational research.免疫治疗中的肿瘤类器官:从疾病建模到转化研究。
J Immunother Cancer. 2025 Jul 15;13(7):e011733. doi: 10.1136/jitc-2025-011733.
7
The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma.PLEKHA1-TACC2融合基因通过在食管鳞状细胞癌中形成血管拟态驱动肿瘤发生。
Cell Death Differ. 2025 Jul 5. doi: 10.1038/s41418-025-01536-1.
8
Endothelial metabolic zonation in the vascular network: a spatiotemporal blueprint for angiogenesis.血管网络中的内皮代谢分区:血管生成的时空蓝图。
Am J Physiol Heart Circ Physiol. 2025 Aug 1;329(2):H340-H357. doi: 10.1152/ajpheart.00352.2025. Epub 2025 Jun 27.
9
Precision Medicine: IL-1RA and Pancreatic Cancer Organoids.精准医学:白细胞介素-1受体拮抗剂与胰腺癌类器官
Biology (Basel). 2025 May 25;14(6):604. doi: 10.3390/biology14060604.
10
Organoids technology in cancer research: from basic applications to advanced models.癌症研究中的类器官技术:从基础应用到先进模型
Front Cell Dev Biol. 2025 May 22;13:1569337. doi: 10.3389/fcell.2025.1569337. eCollection 2025.